



## PRESS RELEASE

December 14th, 2011

### **Isentio is granted NOK 2.6M to develop tools for diagnosis of fungal infections**

**Isentio AS has been awarded a grant of NOK 2.6M from Innovation Norway to develop a sequence based analysis tool for the diagnosis of fungal infections. ARUP Laboratories, Salt Lake City, Utah, USA will be a partner in this project.**

Fungi can cause serious infections, particularly in immunocompromised patients. Good tools for fungal identification are lacking. This becomes an even bigger problem as an increasing number of fungi are causing infections and their clinical context is not well understood.

Isentio AS and ARUP Laboratories are heading up a joint project to create a fungal database that provides information important to identifying and reporting out clinical fungal samples, whether they be as isolates or as a mix with other fungi or bacteria.

"We are extremely happy to have ARUP Laboratories as a partner in the project. As one of the leading reference laboratories in the world, with thousands of samples being analyzed each day and a worldwide leader in innovative laboratory research and development, they are the perfect partner for such a project" says Camilla Huse Bondesson, CEO of Isentio.

DNA sequence based identification of fungal organisms has the potential to become a powerful tool for routine analysis of clinical samples. Particularly since mixed infections now can be identified with the RipSeq Mixed software from Isentio. Isentio will therefore continue to develop the [RipSeq solution](#) to enable identification of fungal infections by direct sequencing of clinical specimen.

#### **About Isentio AS ([www.isentio.com](http://www.isentio.com))**

Isentio offers unique, online software solutions to facilitate analysis, interpretation and management of DNA sequencing data. RipSeq sequence-based analysis reduces the time needed to identify infectious pathogens, in single or poly-microbial samples, by up to 90% and provides answers where other methods fail. Fast, precise pathogen identification supports selection of optimal antibiotic regimes with the potential to reduce health care costs.

For additional information please contact:

#### **Bjarte Karlsen**

COO, President Isentio LLC  
P: +1 (408) 636 8951  
E: [bjarte.karlsen@isentio.com](mailto:bjarte.karlsen@isentio.com)

#### **Camilla Huse Bondesson**

CEO  
P: +46 70 666 8209  
E: [camilla.huse.bondesson@isentio.com](mailto:camilla.huse.bondesson@isentio.com)

Isentio AS  
Thormoehlensgate 51  
N 5006 Bergen  
Norway  
Phone: +46 70 666 8209

Isentio US LLC  
440 North Wolfe road MS - 143  
Sunnyvale  
CA 94085 USA  
Phone: +1 408 636 8951

Reg no: 989 153 846  
Reg Office: Bergen  
W: [www.isentio.com](http://www.isentio.com)  
M: [mail@isentio.com](mailto:mail@isentio.com)

If you do not wish to receive any further communications from Isentio please [click here](#) to unsubscribe.

Click [here](#) for a webversion